3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
3
Completed
2
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
15
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Uveal Melanoma
3
Sarcoma
3
Prostatic Neoplasms
3
Neoplasm Metastasis
3
Pancreatic Neoplasms
2
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Brain Neoplasms
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous-Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Diseases
1
Osteosarcoma
1
Neoplastic Cells, Circulating
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Nasopharyngeal Carcinoma
1
Metastatic Microsatellite Stable Colorectal Cancer
1
Kidney Neoplasms
1
Hypoxia
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Interventions
Radiation Dose Hypofractionation
2
toripalimab
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
envafolimab
1
brostallicin
1
anlotinib
1
Temozolomide
1
Ritonavir
1
Radiotherapy
1
Phlebotomy
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Ipilimumab
1
Indinavir
1
Doxorubicin
1
Diathermy
1
Blood Specimen Collection
1
Biopsy, Needle
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Histiocytoma, Malignant Fibrous
×
Ipilimumab
×
Clear all
NCT04480502
2024-05-17
ENVASARC
Tracon Pharmaceuticals Inc.
Phase 2
Unknown
207 enrolled